Chimeric antigen receptor (CAR) modified T cells emerged as promising immunotherapy in refractory lymphoid malignancies.
Four months later, rituximab-lenalidomide cycle was initiated for lymphoma recurrence. On day 11 of the third cycle, the patient developed confusion and myoclonus. On day 12, MRI brain revealed frontoparietal cortical fluid-attenuated inversion recovery hyperintensities. CSF was normal; cEEG showed GPDs. Dexamethasone was initiated; AED doses were escalated. After 4 doses of dexamethasone, he improved electroclinically. On day 16, fosphenytoin was discontinued; levetiracetam and lacosamide were continued. Neurotoxicity completely resolved.
Case 3
A 51-year-old man developed confusion on day 4 postinfusion. On day 7, levetiracetam was started. On day 8, his encephalopathy worsened; dexamethasone was administered. cEEG showed GPDs (figure). He became obtunded requiring intubation. On day 9, MRI brain was normal. After 5 doses of dexamethasone, he improved electroclinically. On day 13, levetiracetam was discontinued. He remained intubated on propofol due to respiratory and cardiovascular failure that required tocilizumab on day 14. On day 19, EEG was normal; clinical neurotoxicity resolved. 
Case 4
An 82-year-old man developed confusion and somnolence on day 17 postinfusion. After levetiracetam administration, cEEG showed GPDs (figure). On day 18, transient electroclinical improvement occurred after levetiracetam increase. On day 20, dexamethasone was initiated. On day 22, the cognition significantly improved. On day 23, his cEEG was normal; levetiracetam was continued.
Discussion
Among all patients with chemotherapy-refractory DLBCL-4 receiving JCAR017 at Massachusetts General Hospital, 4 had neurotoxicity and GPDs. Encephalopathy developed 5-17 days after infusion, lasting 4-14 days, consistent with literature.
1 Only 2/4 patients had low-grade fever at neurotoxicity onset. Neurotoxicity resolved after fever abatement. Only patient 3 had severe persistent CRS despite resolved neurotoxicity. We diagnosed CRS based on clinical signs and symptoms.
1 CRS grading was based on management algorithm ranging from mild (grade 1) to life-threatening (grade 4). 1 All patients had increasing CRP and ferritin associated with electroclinical worsening. These trended down after dexamethasone initiation and preceded electroclinical improvement. Only patient 3 had CRS at time of neurotoxicity onset. CRS usually presents 6-20 days postinfusion, likely due to proinflammatory cytokines. 1 Neurotoxicity varies from mild encephalopathy to status epilepticus. 1 In the TRANSCEND trial, 0% had ≥3 grade CRS and 14% neurotoxicity. 2 In the Zuma-1 trial, 20% displayed ≥3 grade CRS and 29% neurotoxicity. 3 It is unknown whether the same mechanisms underlie both neurotoxicity and CRS. 2 The second patient developed recurrent neurotoxicity during the third rituximab-lenalidomide cycle, 3 months after JCAR017. One possible explanation could be that lenalidomide may have potentiated the JCAR017-related neurotoxic adverse effects as seen postinfusion. Two studies reported in vivo potentiation of CAR T cells in animal models after receiving lenalidomide. 4, 5 However, this observation has so far not been described in humans. Another possibility would be an independent neurotoxic process as can be seen in posterior reversible encephalopathy syndrome secondary to lenalidomide/rituximab infusion.
Clinical worsening correlated with peak worsening of GPDs, 24-72 hours after encephalopathy onset. AED addition or escalation did not result in electroclinical response. All patients showed sustained improvement to dexamethasone. Levetiracetam was the first line, followed by fosphenytoin, then lacosamide.
Animal and human studies reveal cortical and subcortical involvement in generating GPDs. 6 Potential mechanisms of GPDs and encephalopathy include neuronal dysfunction by proinflammatory cytokines, or direct T-cell-mediated effects on the brain, resulting in thalamocortical network disruption generating synchronous GPDs. 7 Our patients received 10 mg IV dexamethasone every 12 hours, similar to concurrent CAR T-cell-related grade 3 or 4 neurotoxicity recommendations. Our patients received dexamethasone until improvement to grade 1 neurotoxicity. It is possible that dexamethasone halted cytokine-mediated effects that caused neuronal and thalamocortical hyperexcitability evidenced by GPDs.
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